CELIA
OREJA GUEVARA
Profesora asociada de Ciencias de la Salud
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital Clínico San Carlos de Madrid (132)
2024
-
Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis
Multiple Sclerosis and Related Disorders, Vol. 84
-
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies
Journal of neurology, Vol. 271, Núm. 1, pp. 472-485
-
Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
Frontiers in Neurology, Vol. 15
2023
-
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets
Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 15-21
-
Assisted Reproductive Techniques in Multiple Sclerosis: Recommendations from an Expert Panel
Neurology and Therapy, Vol. 12, Núm. 2, pp. 427-439
-
Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
Digital Health, Vol. 9
-
Diagnosis and treatment of progressive multiple sclerosis: A position paper
European Journal of Neurology, Vol. 30, Núm. 1, pp. 9-21
-
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883
-
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary
Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 5-13
-
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence
Multiple Sclerosis and Related Disorders, Vol. 69
-
Monitoring response to disease-modifying treatment in multiple sclerosis
Neurology Perspectives, Vol. 3, Núm. 2
-
Predictors of treatment switching in the Big Multiple Sclerosis Data Network
Frontiers in Neurology, Vol. 14
-
Ravulizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Annals of Neurology, Vol. 93, Núm. 6, pp. 1053-1068
-
Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study
Multiple Sclerosis and Related Disorders, Vol. 69
-
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644
-
Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience
Frontiers in Neurology, Vol. 14
-
XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)
Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30
-
XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)
Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60
2022
-
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
Frontiers in Immunology, Vol. 13
-
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Multiple Sclerosis Journal, Vol. 28, Núm. 5, pp. 842-846